Wasatch Advisors LP Acquires 14,296 Shares of TransMedics Group, Inc. $TMDX

Wasatch Advisors LP grew its holdings in TransMedics Group, Inc. (NASDAQ:TMDX) by 4.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 346,144 shares of the company’s stock after acquiring an additional 14,296 shares during the period. Wasatch Advisors LP owned about 1.00% of TransMedics Group worth $34,410,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also made changes to their positions in the company. Louisiana State Employees Retirement System purchased a new stake in shares of TransMedics Group during the first quarter worth about $1,511,000. Fiduciary Alliance LLC purchased a new position in TransMedics Group in the 1st quarter worth approximately $200,000. Total Clarity Wealth Management Inc. lifted its holdings in TransMedics Group by 5.1% in the 1st quarter. Total Clarity Wealth Management Inc. now owns 2,322 shares of the company’s stock worth $231,000 after purchasing an additional 112 shares in the last quarter. Values First Advisors Inc. boosted its stake in TransMedics Group by 3.1% in the 1st quarter. Values First Advisors Inc. now owns 5,944 shares of the company’s stock worth $591,000 after purchasing an additional 181 shares during the period. Finally, Campbell Newman Asset Management Inc. boosted its stake in TransMedics Group by 1.7% in the 1st quarter. Campbell Newman Asset Management Inc. now owns 12,248 shares of the company’s stock worth $1,218,000 after purchasing an additional 209 shares during the period. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

TransMedics Group Stock Down 12.0%

Shares of TMDX opened at $68.44 on Friday. The company has a debt-to-equity ratio of 1.70, a current ratio of 6.74 and a quick ratio of 6.19. The stock has a market capitalization of $2.37 billion, a price-to-earnings ratio of 15.55 and a beta of 1.91. TransMedics Group, Inc. has a 1 year low of $60.10 and a 1 year high of $156.00. The business’s 50 day simple moving average is $79.48 and its 200-day simple moving average is $110.46.

TransMedics Group (NASDAQ:TMDX) last posted its earnings results on Tuesday, May 5th. The company reported $0.30 earnings per share for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.32). TransMedics Group had a net margin of 27.04% and a return on equity of 22.38%. The business had revenue of $173.93 million during the quarter, compared to analysts’ expectations of $174.44 million. During the same period last year, the business posted $0.70 earnings per share. The company’s revenue for the quarter was up 21.2% compared to the same quarter last year. As a group, equities analysts expect that TransMedics Group, Inc. will post 1.98 earnings per share for the current fiscal year.

Insider Activity at TransMedics Group

In other news, Director Thomas J. Gunderson sold 9,624 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $75.06, for a total value of $722,377.44. Following the sale, the director directly owned 16,642 shares in the company, valued at $1,249,148.52. The trade was a 36.64% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 6.90% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on TMDX shares. Needham & Company LLC reduced their price objective on shares of TransMedics Group from $174.00 to $142.00 and set a “buy” rating on the stock in a research report on Wednesday, May 6th. TD Cowen decreased their price target on shares of TransMedics Group from $190.00 to $120.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Oppenheimer downgraded shares of TransMedics Group from an “outperform” rating to a “market perform” rating in a report on Wednesday, May 6th. UBS Group reissued a “hold” rating on shares of TransMedics Group in a report on Tuesday, May 26th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of TransMedics Group in a research report on Tuesday, June 9th. Six investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $134.50.

About TransMedics Group

TransMedics Group, Inc is a medical device company headquartered in Andover, Massachusetts, that specializes in advanced organ preservation and transport systems for transplantation. The company’s flagship technology, the Organ Care System (OCS), maintains donor organs in a near-physiologic, warm, beating state during transportation, with the aim of extending preservation times and improving post‐transplant outcomes. TransMedics’ solutions address a critical need in transplantation by reducing ischemic injury and expanding the donor organ pool.

TransMedics currently markets two commercially available OCS platforms.